Anaemia in Cancer Patients: Advances and Challenges in the Era of Precision Oncology.

Federica Miglietta, Mario Pirozzi, Michele Bottosso, Carla Pisani, Pierfrancesco Franco, Valentina Guarnieri, Alessandra Gennari
{"title":"Anaemia in Cancer Patients: Advances and Challenges in the Era of Precision Oncology.","authors":"Federica Miglietta, Mario Pirozzi, Michele Bottosso, Carla Pisani, Pierfrancesco Franco, Valentina Guarnieri, Alessandra Gennari","doi":"10.1016/j.critrevonc.2025.104788","DOIUrl":null,"url":null,"abstract":"<p><p>Anaemia in cancer patients is an independent prognostic factor associated with reduced survival and increased morbidity. Aetiology of anaemia in cancer patients is multifactorial, involving complex interactions between the cancer itself, treatment modalities, and patient-specific factors. Although anaemia is traditionally associated with cytotoxic chemotherapy, newer drugs can still cause haemoglobin reduction by blood loss, erythrocytes impaired production and increased destruction or reduced survival. A view on the different impact of newer drugs will be presented in our review. Data on the impact of anaemia on quality of life, according to several scales specifically designed for cancer-associated anaemia, will also be reported. Finally, we report on recent guidelines and advances in anaemia management: oral and intravenous iron supplementation, red blood cells transfusions and erythropoiesis-stimulating agents.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104788"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.critrevonc.2025.104788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Anaemia in cancer patients is an independent prognostic factor associated with reduced survival and increased morbidity. Aetiology of anaemia in cancer patients is multifactorial, involving complex interactions between the cancer itself, treatment modalities, and patient-specific factors. Although anaemia is traditionally associated with cytotoxic chemotherapy, newer drugs can still cause haemoglobin reduction by blood loss, erythrocytes impaired production and increased destruction or reduced survival. A view on the different impact of newer drugs will be presented in our review. Data on the impact of anaemia on quality of life, according to several scales specifically designed for cancer-associated anaemia, will also be reported. Finally, we report on recent guidelines and advances in anaemia management: oral and intravenous iron supplementation, red blood cells transfusions and erythropoiesis-stimulating agents.

癌症患者贫血:精准肿瘤学时代的进展与挑战。
癌症患者的贫血是与生存率降低和发病率增加相关的独立预后因素。癌症患者贫血的病因是多因素的,涉及癌症本身、治疗方式和患者特异性因素之间复杂的相互作用。虽然贫血传统上与细胞毒性化疗有关,但新药物仍可因失血导致血红蛋白减少,红细胞生成受损,破坏增加或存活率降低。我们将在综述中介绍新药的不同影响。根据专门为癌症相关贫血设计的几个量表,还将报告有关贫血对生活质量影响的数据。最后,我们报告了贫血管理的最新指南和进展:口服和静脉补铁,红细胞输注和促红细胞生成药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信